These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 19910295)

  • 1. Intravenous and oral sulodexide versus coagulation activation markers in humans.
    Borawski J; Dubowski M; Rydzewska-Rosolowska A; Mysliwiec M
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):596-8. PubMed ID: 19910295
    [No Abstract]   [Full Text] [Related]  

  • 2. Prothrombin fragment 1+2 during oral anticoagulation in congenital nephrotic syndrome.
    Mache CJ; Muntean W; Resch B; Ring E
    Pediatr Nephrol; 1998 Sep; 12(7):617. PubMed ID: 9761365
    [No Abstract]   [Full Text] [Related]  

  • 3. A case report of a paroxysmal nocturnal hemoglobinuria with increased coagulation activation markers while on treatment with LMWH with anti-Xa levels above the therapeutic range.
    Arkel YS; Ku DH; Lake C; Lam X; Spielvogel A
    Thromb Haemost; 2000 Feb; 83(2):348-9. PubMed ID: 10739398
    [No Abstract]   [Full Text] [Related]  

  • 4. Documentation of hypocoagulability by measurement of prothrombin fragment F 1 + 2 when introducing oral anticoagulant therapy.
    Bruhn HD; Liebsch J; Wagner C
    Thromb Res; 1992 Nov; 68(3):317-9. PubMed ID: 1471078
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of sulodexide on plasma transforming growth factor-beta1 in healthy volunteers.
    Borawski J; Dubowski M; Pawlak K; Mysliwiec M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):60-5. PubMed ID: 19117965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of blood coagulation activation and oral anticoagulants in patients with mechanical heart valve prostheses.
    Barcellona D; Mameli G; Marongiu F
    Thromb Res; 1996 Feb; 81(3):403-6. PubMed ID: 8928097
    [No Abstract]   [Full Text] [Related]  

  • 8. Coagulation activation and reactive fibrinolysis in patients receiving oral anticoagulation after total hip or knee replacement.
    van Wersch JW; de Vries-Hanje JC; Oosterbos C
    Blood Coagul Fibrinolysis; 1994 Aug; 5(4):605-8. PubMed ID: 7841318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men.
    Lip GY; Blann AD
    J Hypertens; 1998 Oct; 16(10):1557-9. PubMed ID: 9814630
    [No Abstract]   [Full Text] [Related]  

  • 10. Acenocoumarol decreases tissue factor-dependent coagulation during systemic inflammation in humans.
    Hollenstein U; Homoncik M; Knöbl P; Pernerstorfer T; Graggaber J; Eichler HG; Handler S; Jilma B
    Clin Pharmacol Ther; 2002 May; 71(5):368-74. PubMed ID: 12011822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous infusion of a standard coagulation-active phospholipid complex in uremic tendency to bleeding. Normalization of thrombin formation and prothrombin consumption].
    Schimpf K; Hanf-Hoppe HW; Immich H
    Med Welt; 1972 Sep; 23(37):1258-60. PubMed ID: 5078657
    [No Abstract]   [Full Text] [Related]  

  • 12. [Value of molecular markers for administration of anticoagulant therapy after heart valve replacement].
    Dahm M; Lotz J; Hafner G; Oelert H; Prellwitz W
    Z Kardiol; 1998; 87 Suppl 4():42-5. PubMed ID: 9857466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulodexide induces hepatocyte growth factor release in humans.
    Borawski J; Dubowski M; Pawlak K; Mysliwiec M
    Eur J Pharmacol; 2007 Mar; 558(1-3):167-71. PubMed ID: 17258198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Letter to the editor.
    Odak S
    J Orthop Trauma; 2009 Aug; 23(7):550; author reply 550. PubMed ID: 19633468
    [No Abstract]   [Full Text] [Related]  

  • 17. Prothrombin fragment 1 + 2 and intensity of treatment with oral anticoagulants.
    Mannucci PM; Bottasso B; Tripodi A; Bianchi Bonomi A
    Thromb Haemost; 1991 Dec; 66(6):741. PubMed ID: 1796423
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative anticoagulant and platelet modulatory effects of enoxaparin and sulodexide.
    Adiguzel C; Iqbal O; Hoppensteadt D; Jeske W; Cunanan J; Litinas E; He Zhu ; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):501-11. PubMed ID: 19703818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in molecular markers of hemostatic and fibrinolytic activation under various sampling conditions using vacuum tube samples from healthy volunteers.
    Omote M; Asakura H; Takamichi S; Shibayama M; Yoshida T; Kadohira Y; Maekawa M; Yamazaki M; Morishita E; Nakao S; Wada T
    Thromb Res; 2008; 123(2):390-5. PubMed ID: 18579183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables.
    Kluft C; Meijer P; LaGuardia KD; Fisher AC
    Contraception; 2008 Feb; 77(2):77-83. PubMed ID: 18226669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.